

Registration number 653316

DML Pharma Operations Advisory Services Limited

Abridged accounts

for the year ended 30th June 2025

DML Pharma Operations Advisory Services Limited

Contents

| | Page |
|---|--------------|
| Directors and other information | 1 |
| Extract from the Directors' report in accordance with section 329 of the Companies Act 2014 | 2 |
| Statement of directors' responsibilities | 3 |
| Abridged balance sheet | 4 - 5 |
| Notes to the abridged financial statements Including statement of accounting policies | 6 - 9 |

DML Pharma Operations Advisory Services Limited

Directors and other information

| | |
|-------------------|---|
| Directors | Danny McLaughlin Fionnuala McLaughlin |
| Secretary | Danny McLaughlin |
| Company number | 653316 |
| Registered office | Knockaraha Belclare Westport Co. Mayo |
| Accountants | Coll & Co Chartered accountant & taxation advisors Pier Road Barna Co. Galway |
| Bankers | Allied Irish Banks PLC Shop Street Westport Co. Mayo |

DML Pharma Operations Advisory Services Limited

Extract from the Directors' report in accordance with section 329 of the Companies Act 2014.

Directors' and secretary and their interests in shares of the company

The directors and secretary who served during the year and their interests in the company are as stated below:

| | Ordinary shares | |
|--------------------------|------------------------|-----------------|
| | 30/06/25 | 30/06/24 |
| Danny McLaughlin | 50 | 50 |
| Fionnuala McLaughlin | 50 | 50 |
| Company secretary | | |
| Danny McLaughlin | - | - |

The original report was approved by the board on 4 March 2026 and signed on its behalf by Danny McLaughlin and Fionnuala McLaughlin.

DML Pharma Operations Advisory Services Limited

Statement of directors responsibilities and declaration on unaudited financial statements

General responsibilities

The directors are responsible for preparing the Annual Report and the financial statements in accordance with applicable Irish law and generally accepted accounting practice in Ireland including the accounting standards issued by the Financial Reporting Council and published by the Institute of Chartered Accountants in Ireland.

Irish Company law requires the directors to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period. In preparing those financial statements, the directors are required to:

- select suitable accounting policies and then apply them consistently
- make judgements and estimates that are reasonable and prudent
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the company and to enable them to ensure that the financial statements are prepared in accordance with accounting standards generally accepted in Ireland and with Irish statute comprising the Companies Act 2014. They are also responsible for safeguarding the assets of the company and hence, for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Directors' declaration on unaudited financial statements

In relation to the financial statements as set out on pages 4 to 9 :

- The directors approve these financial statements and confirm that they are responsible for them, including selecting the appropriate accounting policies, applying them consistently and making, on a reasonable and prudent basis, the judgements underlying them. They have been prepared on the going concern basis on the grounds that the company will continue in business.
- The directors confirm that they have made available to Coll & Co, all the company's accounting records and provided all the information, books or documents necessary for the compilation of the financial statements.
- The directors confirm that to the best of their knowledge and belief, the accounting records reflect all the transactions of the company for the year ended 30th June 2025.

On behalf of the board

Danny McLaughlin
Director

Fionnuala McLaughlin
Director

Date: 4th March 2026

DML Pharma Operations Advisory Services Limited

**Abridged balance sheet
as at 30 June 2025**

| | Notes | 2025 | | 2024 | |
|---|-------|---------|---------|---------|-------|
| | | € | € | € | € |
| Fixed assets | | | | | |
| Tangible assets | 3 | | 1,607 | | 2,076 |
| Current assets | | | | | |
| Cash at bank and in hand | | 1,615 | | 6,742 | |
| | | 1,615 | | 6,742 | |
| Creditors: amounts falling due within one year | | (3,390) | | (4,400) | |
| Net current (liabilities)/assets | | | (1,775) | | 2,342 |
| Total assets less current liabilities | | | (168) | | 4,418 |
| Net (liabilities)/assets | | | (168) | | 4,418 |
| Capital and reserves | | | | | |
| Called up share capital | | | 100 | | 100 |
| Profit and loss account | | | (268) | | 4,318 |
| Equity shareholders' funds | | | (168) | | 4,418 |

The directors have relied on the specified exemption contained in Section 352 of the Companies Act 2014 on the grounds that the company is entitled to the benefit of that exemption as a small company and the abridged financial statements have been properly prepared in accordance with Section 353.

The directors state that:

- (a) the company is availing itself of the exemption provided for by Chapter 15 of Part 6 of the Companies Act 2014;
- (b) the company is availing itself of the exemption on the grounds that Section 358 is complied with;
- (c) no notice under subsection (1) of Section 334 has, in accordance with subsection (2) of that section, been served on the company;
- (d) they acknowledge the company's obligations under Companies Act 2014, to keep adequate accounting records and to prepare Financial Statements which give a true and fair view of the assets, liabilities and financial position of the company at the end of its financial year and of its profit or loss for such a year and to otherwise comply with the provisions of Companies Act 2014 relating to Financial Statements so far as they are applicable to the company.

The notes on pages 6 to 9 form an integral part of these financial statements.

DML Pharma Operations Advisory Services Limited

The abridged accounts were approved by the Board on 4 March 2026 and signed on its behalf by

.....
Danny McLaughlin
Director

.....
Fionnuala McLaughlin
Director

DML Pharma Operations Advisory Services Limited
Notes to the abridged financial statements
for the year ended 30 June 2025

1. Statement of accounting policies

The following accounting policies have been applied consistently in dealing with items which are considered material in relation to the company's financial statements.

1.1. Basis of preparation

The unaudited accounts have been prepared in accordance with accounting standards generally accepted in Ireland and the Companies Act 2014. Accounting Standards generally accepted in Ireland in preparing financial statements giving a true and fair view are those issued by the Financial Reporting Council.

1.2. Turnover policy

Turnover represents the total invoice value, excluding value added tax, of sales made during the year.

1.3. Tangible assets and depreciation

Tangible assets are stated at cost less accumulated depreciation and accumulated impairment loss. Cost includes all costs that are directly attributable to bringing the asset into working condition for its intended use.

Depreciation

Depreciation is provided on all tangible assets, at rates calculated to write off the cost less estimated residual value, of each asset systematically over its expected useful life, as follows:

| | | |
|-------------------------------------|---|---------------------|
| Fixtures, fittings and equipment | - | 12.5% Straight Line |
|-------------------------------------|---|---------------------|

1.4. Taxation

The yearly charge for taxation is based on the profit for the year and is calculated with reference to the tax rates applying at the balance sheet date.

DML Pharma Operations Advisory Services Limited
Notes to the abridged financial statements
for the year ended 30 June 2025

..... continued

2. Employees

There were no employees during the year apart from the directors.

Number of employees

The average monthly numbers of employees
(including the directors) during the year were:

| | 2025 | 2024 |
|----------------|-------------|-------------|
| Directors | 2 | 2 |
| Administration | - | 1 |
| | 2 | 3 |
| | 2 | 3 |

Employment costs

| | 2025 | 2024 |
|--------------------|-------------|-------------|
| | € | € |
| Wages and salaries | 8,591 | 28,751 |
| | 8,591 | 28,751 |
| | 8,591 | 28,751 |

2.1. Directors' remuneration

| | 2025 | 2024 |
|-----------------------------------|-------------|-------------|
| | € | € |
| Remuneration and other emoluments | 8,591 | 25,835 |
| | 8,591 | 25,835 |
| | 8,591 | 25,835 |

DML Pharma Operations Advisory Services Limited
Notes to the abridged financial statements
for the year ended 30 June 2025

..... continued

3. Fixed assets

| | Tangible fixed assets | Total |
|------------------------|--------------------------------------|--------------|
| | € | € |
| Cost | | |
| At 1 July 2024 | 3,753 | 3,753 |
| At 30 June 2025 | 3,753 | 3,753 |
| Depreciation | | |
| At 1 July 2024 | 1,677 | 1,677 |
| Charge for year | 469 | 469 |
| At 30 June 2025 | 2,146 | 2,146 |
| Net book values | | |
| At 30 June 2025 | 1,607 | 1,607 |
| | | |
| Cost | | |
| At 30 June 2024 | 3,753 | 3,753 |
| Depreciation | | |
| At 1 July 2023 | 1,208 | 1,208 |
| Charge for year | 469 | 469 |
| At 30 June 2024 | 1,677 | 1,677 |
| Net book values | | |
| At 30 June 2024 | 2,076 | 2,076 |

4. Share capital

| | 2025 | 2024 |
|---|-------------|-------------|
| | € | € |
| Authorised equity | | |
| 1,000,000 Ordinary shares of €1 each | 1,000,000 | 1,000,000 |
| Allotted, called up and fully paid share capital | | |
| 100 Ordinary shares of €1 each | 100 | 100 |
| | | |
| Allotted and called up share capital | | |
| Amounts presented in equity | | |
| 100 Ordinary shares of €1 each | 100 | 100 |

DML Pharma Operations Advisory Services Limited
Notes to the abridged financial statements
for the year ended 30 June 2025

..... continued

5. Accounting periods

The current accounts are for a full year. The comparative accounts are for a full year.

6. Approval of financial statements

The board of directors approved these financial statements for issue on 4 March 2026.